Hansoh Pharma Deal History & Licensing Activity
Hansoh Pharma is a large pharma headquartered in China. Over the past three years, Hansoh Pharma has been involved in 8 licensing and acquisition transactions, with a primary focus on Oligonucleotides (2 deals).
Deals (12mo)
1
Active Trials
20
Top Modality
Oligonucleotides
Focus Area
Option Deals
Hansoh Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Hansoh Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| mRNAi GOLD platform (siRNA therapies, 3 targets) | Hansoh Pharmaceutical | Oligonucleotides | Unknown | option | Jun 23, 2026 |
Hansoh Pharma Pipeline Focus
Therapeutic areas and modalities where Hansoh Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Hansoh Pharma Strategic Signals
Key indicators of Hansoh Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Hansoh Pharma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Hansoh Pharma Licensing & Deal Activity
Hansoh Pharma is a large pharma company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Hansoh Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Hansoh Pharma include Option Deals (3 deals and trials), Oncology (3 deals and trials), Women's Health (2 deals and trials), and Metabolic (1 deal and trial). In terms of modality, Hansoh Pharma has shown particular interest in oligonucleotides, small molecules, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hansoh Pharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Hansoh Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.